BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Extra | May 29, 2018
Preclinical News

IL-1 blockade to treat CAR T side effects

In a pair of papers published Monday in Nature Medicine, researchers from the Sloan Kettering Institute and the San Raffaele Hospital Scientific Institute suggest blocking the IL-1 receptor could help treat side effects of CAR...
BC Innovations | May 23, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Patient sample and mouse studies suggest inhibiting NOS2 could help treat psoriatic arthritis. In peripheral blood mononuclear cells (PBMCs) from patients, levels of NOS2 were higher than in healthy volunteers. In a mouse...
BC Innovations | Jan 25, 2017
Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting NOS2 could help treat Marfan syndrome. In aortic tissue samples, levels of NOS2 were higher in patients and a mouse model of Marfan syndrome than in...
BC Innovations | Apr 23, 2015
Translation in Brief

Arginine for Alzheimer's

A group at Duke University has found that blocking overconsumption of arginine in the brain could prevent the early stages of Alzheimer's disease and that - counter to the prevailing view - local immune suppression rather than...
BC Innovations | Aug 14, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers A two-gene signature distinguishes between psoriasis and eczema Human sample studies suggest a two-gene classifier can be used to distinguish between psoriasis and eczema. In skin...
BC Innovations | Jun 26, 2014
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Inducible nitric oxide synthase 2 (NOS2; iNOS); JAK kinase (JAK); signal transducer and activator of transcription 1 (STAT1) Cell culture studies have identified a...
BC Week In Review | Apr 15, 2013
Company News

Merck Research Laboratories other research news

Merck esearchers and colleagues reported that the NOS2 gene is involved in resistance to M. tuberculosis infection. Following inoculation with virulent bacteria, mice lacking NOS2 contracted consolidating pneumonitis and died within 37.7 days while wild-type...
BC Innovations | Jun 28, 2012
Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program ( see "Repurposing pharma compounds"). The compounds provided by...
BC Innovations | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In vitro and mouse studies suggest iNOS inhibitors could...
Items per page:
1 - 10 of 49